- NSI-566 shown to have restorative function in primate paralysis model -
- NSI-566 transplantation resulted in measurable improvement in forelimb function -
GERMANTOWN, Md., March 14 (Bernama) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, highlighted the publication of a manuscript in Nature Medicine showing that NSI-566, Neuralstem´s lead cell therapy candidate, provided meaningful improvement in forelimb function in a non-human primate model of acute spinal cord injury. The full manuscript can be found here.
The manuscript, entitled Restorative Effects of Human Neural Stem Cell Grafts on the Primate Spinal Cord,´ involved a study to evaluate the potential benefits of transplanting NSI-566 into rhesus monkeys two weeks after they received a hemisection lesion of the cervical spinal cord. For the full text, click here.